.webp)
Samsung Biologics will launch ADC drug product services by 2027, improving development and manufacturing support for worldwide pharmaceutical companies.
Samsung Biologics has announced plans to introduce an antibody-drug conjugate (ADC) drug product service in the very first quarter of 2027, as the company grows its contract development organization (CDO) business and improves its manufacturing capabilities. Pharmacological product services focus on transforming pharmacological components into finished dosage forms suitable for clinical studies and commercial manufacture. This stage is especially important for ADCs, which combine antibodies with strong cancer-fighting compounds. Because these medications are complex and chemically sensitive, formulation and stability problems can create delays in development and complicate regulatory evaluations.
"ADCs present unique stability challenges as toxic payloads are attached to antibodies," said Lee Sang-myung, vice president and head of business strategy at Samsung Biologics, who spoke at the J.P. Morgan Healthcare Conference. Customers want pharmaceutical goods that are manufactured quickly and near to where they are developed, usually by freezing and drying to improve stability and storage. As a result, the demand for ADC health product services is continuously increasing. Samsung Biologics has already ordered the necessary supplies, and installation is expected to start by the end of the year. Since starting its CDO business in 2018, the company has signed 164 development contracts, including five ADC projects, resulting in 49 investigational new medication approvals.
The company has nine proprietary technology platforms that support different stages of medication development. Its S-CHOice cell line platform was recently improved, increasing antibody production from roughly 7 to 13 grams per liter. These advancements resulted in the reduction of development times for monoclonal and bispecific antibodies, while ADC medicinal substance manufacturing now takes about 14.5 months on average. Samsung Biologics is also expanding its research products with the organoid platform, which tests cancer treatments using patient-derived tumor models. With this development, Samsung Biologics aims to offer complete services from early research to manufacturing, positioning itself for future growth in the worldwide biologic industry.
.webp)
.webp)
